Opinion: NEJM sheds light on payments to doctors
It should come as no surprise that pharmaceutical companies pay doctors for a variety of reasons such as research, lecturing, and teaching. Such payments are justified as these physicians tend to be in demand as experts and their expertise is valued. They can't be expected to do this work pro bono – their time is valuable. However, such payments are viewed with great suspicion. Industry critics are quick to charge that what companies are really doing is currying favor with doctors so that they will write more prescriptions for their drugs. This type of "manipulation" is believed to be a conflict-of-interest.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- IOM Identifies GME Problems, Calls for Finance Changes
- Healthcare Costs Start With What We Eat
- Handshaking Spreads Germs. Get Over It.
- Revenue Cycles Get a Boost from Simple JPEG Files
- Hospitals Likely to Outsource ICD-10 at Launch
- Anatomy of 3 Health System Rebranding Efforts